Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Pliant Therapeutics Analyst Ratings
Neutral Rating on Pliant Therapeutics Amid Early Promising Data and Uncertainties
Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial
Express News | Pliant Therapeutics Inc: Pln-101095 Was Generally Well Tolerated Across All Doses
Express News | Pliant Therapeutics Announces Interim Phase 1 Data Fro First Three Of Five Potential Cohorts Of Phase 1 Dose Escalation Trial Of PLN-101095; Says Antitumor Activity Observed With Confirmed Partial Responses In 50% Of Patients
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests
Express News | Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future
H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Hold Rating
Pliant Therapeutics Is Maintained at Neutral by Citigroup
Pliant Therapeutics Price Target Cut to $1.50/Share From $4.00 by Citigroup
Hold Rating on Pliant Therapeutics Amid Trial Discontinuation and Safety Concerns
Pliant Downgraded at Stifel on Bexotegrast Trial Discontinuation
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Cantor Fitzgerald Reinstates Neutral on Pliant Therapeutics
Pliant Therapeutics Is Maintained at Equal-Weight by Wells Fargo
CCORF Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $4
Oppenheimer Maintains Pliant Therapeutics(PLRX.US) With Hold Rating
Analysts Conflicted on These Healthcare Names: Pliant Therapeutics (PLRX) and Capricor Therapeutics (CAPR)